Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) highlighted groundbreaking advancements in optical genome mapping (OGM) with its Saphyr system during a recent symposium. Notable achievements include the ability to assess large genomic repeat expansions previously deemed unmeasurable. Clinical validations presented suggest that Saphyr enhances diagnostic accuracy, exemplified by a 25% increase in diagnostic yield for undiagnosed genetic diseases. The University of Iowa and KU Leuven also developed cost-effective assays for Facioscapulohumeral Muscular Dystrophy (FSHD) testing, advancing clinical diagnostics in pediatric genetic disorders.
Bionano Genomics (BNGO) announced positive preliminary findings on its Saphyr system, presented at the Next-Generation Cytogenomics Symposium. The system demonstrated superior performance over the Oncoscan array for detecting structural and copy number variations in solid tumors. Six studies highlighted Saphyr's capability to unveil complex genomic changes in various cancers, including brain and breast cancers, revealing new therapeutic targets. The studies showed that Saphyr achieved 100% concordance with existing testing methods while offering faster, cost-effective solutions for clinical applications.
Bionano Genomics (Nasdaq: BNGO) announced its compliance with Nasdaq's minimum bid price requirement. The company received a notification confirming that its common stock closing bid price has been at $1.00 or greater for the last 10 consecutive business days, from December 29, 2020, to January 12, 2021. This achievement fulfills the Listing Rule 5550(a)(2) criteria, and the matter is now considered closed.
Bionano Genomics (BNGO) announced successful results from Saphyr users at the Next-Generation Cytogenomics Symposium, demonstrating its efficacy in analyzing hematological malignancies. Saphyr identifies actionable genetic variants better than traditional cytogenetic methods, such as karyotyping and FISH, while offering faster results at a lower cost. KU Leuven Hospitals is adopting the Saphyr-based assay for routine Acute Lymphoblastic Leukemia diagnostics, showcasing its potential to streamline clinical workflows and improve diagnostic accuracy.
Bionano Genomics, Inc. (BNGO) has successfully closed its underwritten public offering of 33,368,851 shares at $3.05 per share, raising approximately $101.8 million in gross proceeds. This offering includes the full exercise of the underwriters' option to purchase 4,352,458 additional shares. The shares were offered under a previously filed shelf registration statement and are designed to support Bionano's genome analysis services and products.
Bionano Genomics presented findings at the Next-Generation Cytogenomics Symposium, showcasing the Saphyr system's effectiveness in genetic testing. Notable achievements include a 100% concordance in prenatal testing between Saphyr and standard methods like karyotyping, leading to quicker and cost-effective results. Studies across the US, Europe, and China demonstrated Saphyr's reproducibility and ability to resolve rare genetic diseases. Experts from various institutions highlighted Saphyr's advantages in uncovering actionable insights, thereby enhancing diagnostic capabilities in genetic disorders.
Bionano Genomics (Nasdaq: BNGO) announced the publication of findings from the COVID-19 Host Genome Structural Variant Consortium. The study utilized the Saphyr System to identify significant structural variants (SVs) linked to immune responses and disease severity in COVID-19 patients. Analysis of 37 ICU patients revealed that 12 died, while 25 recovered. Notably, a duplication of the STK26 gene was associated with severe illness, suggesting its potential as a prognostic biomarker. The findings highlight Saphyr’s capability in revealing critical genetic insights overlooked by traditional methods.
Bionano Genomics (BNGO) announced its 5-day Next-Generation Cytogenomics Symposium starting January 11, featuring 33 presentations from Saphyr users at leading medical institutions. The event will spotlight applications of optical genome mapping (OGM) for analyzing genetic diseases and blood cancers, alongside studies validating clinical assays. Notably, a session will focus on COVID-19 related genome studies. CEO Erik Holmlin emphasized Saphyr's capability to detect structural variants that traditional methods overlook, potentially increasing diagnostic yields.
Bionano Genomics has announced the pricing of its public offering of 29,016,393 shares at $3.05 each, aiming for gross proceeds of approximately $88.5 million. The offering, set to close on January 12, 2021, includes a 30-day option for underwriters to purchase an additional 4,352,458 shares. Oppenheimer & Co. serves as the sole book-running manager. Shares are offered under a previously filed shelf registration statement. The proceeds are intended to support Bionano’s genomic analysis tools, particularly the Saphyr system.
Bionano Genomics (Nasdaq: BNGO) announced plans for an underwritten public offering of its common stock, with Oppenheimer & Co. Inc. as the sole book-running manager. All shares offered will be sold by Bionano, and underwriters may purchase an additional 15% to cover over-allotments. This offering is under a previously filed "shelf" registration statement, which is effective until August 2023. The company has emphasized potential risks associated with market conditions and closing conditions of the offering, which may affect completion. Further details will be available in the filed prospectus.